In June, two common dialysis drugs—Naturalyte Acid Concentrate, and its powder form GranuFlo Dry Acid Concentrate—were recalled after an investigation conducted by the Food and Drug Administration (FDA). The drugs have been linked to an increase in heart problems in certain patients. Patients using these drugs are four to six times more likely to suffer cardiac arrest or heart attack than other dialysis patients.
Hemodialysis is a process used to remove waste and excess water from the blood of patients with damaged kidneys. During dialysis, the blood is actually removed from the body and filtered through a machine. The blood travels through tube made of a semi-porous membrane that is surrounded by a dialysis fluid. As the blood travels through the machine, wastes are released into the fluid and the clean blood is returned to patient.
Acid concentrates like GranuFlo and Naturalyte are used in dialysis machines to help regulate acid buildup in the blood. When high doses of these acid concentrates are used, the blood can shift from being acidic to being alkaline. This can lead to a condition known as “metabolic alkalosis.” Metabolic alkalosis is associated with low blood pressure, cardiac arrhythmias, heart attack and cardiac arrest.
Fresenius, the manufacturer of GranuFlo and Naturalyte, is currently under investigation by the FDA for failing to warn patients and doctors of the risks associated with the medications.
If you, or a loved one, suffered serious side effects or a heart attack after dialysis, you may be eligible to file a GranuFlo injury claim against Fresenius. For more information, contact the Wisconsin GranuFlo injury attorneys at Hupy and Abraham. The initial consultation is free and there are no up-front costs. If you don’t win, you don’t pay. To discuss your case with a GranuFlo lawyer, call 800-800-5678.